ArticleVirchows Archiv : an international journal of pathology2017
Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series.
Article in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Establishment and characterization of CHC-X1: the third human combined hepatocellular-cholangiocarcinoma cell line.BMC cancer · 2025Article
- Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma.Frontiers in oncology · 2025Article
- Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach.Biomedicines · 2022Review
- Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms.Cancers · 2022Review
- Salvage living donor liver transplantation for post-resection recurrence of combined hepatocellular carcinoma-cholangiocarcinoma.Korean journal of transplantation · 2021Article
- Postresection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma according to the 2010 World Health Organization classification: single-center experience of 168 patients.Annals of surgical treatment and research · 2021Article
- Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.World journal of surgical oncology · 2020Article
- Breast Metastasis From a Combined Hepatocellular-Cholangiocarcinoma.ACG case reports journal · 2019Article
- Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions.Journal of hepatocellular carcinoma · 2019Review
- cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.Hepatology (Baltimore, Md.) · 2018Article
- Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist.Journal of hepatocellular carcinoma · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare and aggressive primary liver cancer with both hepatocellular and cholangiocellular differentiation. Due to its bi-phenotypic component, cHCC-CC is a heterogeneous tumour and histopathological analysis of metastatic deposits is poorly characterized. In this retrospective study, we describe four patients in whom the histology from resected specimens of both primary and recurrent and/or metastatic tumour was available for comparison and immunohistochemical characterization. Our study shows that recurrent or metastatic deposits replicate the heterogeneity of the primary cHCC-CC, that even originally small foci of divergent differentiation can become predominant later on and that hepatocellular and cholangiocellular components can show different tropism in distant organs. In our experience, the behaviour of recurrent/metastatic cHCC-CC is unpredictable and histological examination is necessary to guide treatment options at present.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.